Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NOCANO: Nivolumab as Neoadjuvant Immunotherapy for Patients With Oral CANcer and Identification of Response-predictive Biomarkers in Tumour Draining Lymph NOdes

NCT07514767 is registered in ClinicalTrials.gov with Prof. Lars Olaf Cardell as lead sponsor.

NCT NCT07514767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07514767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NOCANO: Nivolumab as Neoadjuvant Immunotherapy for Patients With Oral CANcer and Identification of Response-predictive Biomarkers in Tumour Draining Lymph NOdes
Lead sponsor
Prof. Lars Olaf Cardell
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 1, 2026
Completion date
September 30, 2033
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oral squamous cell carcinoma (oscc)